By the nature of GeneSpector's business model, the goal is to take its technology to the global market through subsidiaries with an exit or licensing strategy. Therefore, GeneSpector forms Ventures with professional teams that cover a complete set of competencies to succeed or joins with major global players that integrate the products into their sales networks.
IQS Nano (Acquisition)
IQS nano is a technology company focused on the development and production of optical and functional elements from micro and nanostructures. GeneSpector has acquired a 10% stake in IQS Nano with the aim of joining forces to co-create biomedical applications using nano and micro structured surfaces. The first large joint project is Lab On Card, which was born from an idea and is now an independent company in start-up mode. More information via iqsnano.com
SeveriDx (Venture)
Scientists at the 1st Faculty of Medicine of Charles University in Prague have discovered a biomarker that correlates with the severity of infectious respiratory diseases. In collaboration with GeneSpector, this biomarker was described and confirmed as relevant and subsequently patented. Following a successful academic clinical study, a subsidiary company, SeveriDx, was established with the aim to confirm the clinical relevance of the biomarker in clinical trials, certify it and market it globally. More information via severidx.com
Lab On Card (Venture)
The partnership between GeneSpector and iQS Group revolutionizes diagnostics with Lab On Card technology by combining their unparalleled expertise in clinical diagnostics and advanced nano/micro structuring. The innovative microfluidic plastic card delivers rapid, accurate, and cost-effective diagnostic solutions without the need for instruments, laboratories or medical staff. More information via laboncard.com
ELISA-based Diagnostics of Hereditary Kidney Diseases (License)
Kidney diagnostics with the MUC1 frame shift protein assay – a precise plasma marker for hereditary tubulointerstitial nephropathy. Overcoming DNA sequencing limits, this innovation enables accurate kidney-related diagnoses as easily as an ELISA test and realtime treatment monitoring. The ELISA-based method will be licensed in 2024 and as a RUO product will be delivered into a global market within 2025. License partner: To be published soon.
viRNAtrap CE-IVDR Extraction Kit (License)
Fast and robust nucleic acid extraction is based on magnetic beads technology. viRNAtrap™ CE-IVDR Extraction Kit can be used for manual and automated nucleic acid purification on any open platform. The kit consists of 4 bottles not requiring controlled temperature storage. The isolation process takes 10 minutes only and enables true high-throughput extraction. The kit is CE-IVDR certified and distributed by Immunotech Wolrdwide.